Cargando…

Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial

Background. Buruli ulcer (BU) is a necrotizing skin disease most prevalent among West African children. The causative organism, Mycobacterium ulcerans, is sensitive to temperatures above 37°C. We investigated the safety and efficacy of a local heat application device based on phase change material....

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogel, Moritz, Bayi, Pierre F., Ruf, Marie-Thérèse, Bratschi, Martin W., Bolz, Miriam, Um Boock, Alphonse, Zwahlen, Marcel, Pluschke, Gerd, Junghanss, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706634/ https://www.ncbi.nlm.nih.gov/pubmed/26486698 http://dx.doi.org/10.1093/cid/civ883

Ejemplares similares

Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis
por: Ruf, Marie-Thérèse, et al.
Publicado: (2016)

Locally Confined Clonal Complexes of Mycobacterium ulcerans in Two Buruli Ulcer Endemic Regions of Cameroon
por: Bolz, Miriam, et al.
Publicado: (2015)

A Case of Cutaneous Tuberculosis in a Buruli Ulcer–Endemic Area
por: Bratschi, Martin W., et al.
Publicado: (2012)

Phase Change Material for Thermotherapy of Buruli Ulcer: A Prospective Observational Single Centre Proof-of-Principle Trial
por: Junghanss, Thomas, et al.
Publicado: (2009)

Geographic Distribution, Age Pattern and Sites of Lesions in a Cohort of Buruli Ulcer Patients from the Mapé Basin of Cameroon
por: Bratschi, Martin W., et al.
Publicado: (2013)

Buruli Ulcer in Cameroon: The Development and Impact of the National Control Programme
por: Tabah, Earnest Njih, et al.
Publicado: (2016)

Complete Healing of a Laboratory-Confirmed Buruli Ulcer Lesion after Receiving Only Herbal Household Remedies
por: Andreoli, Arianna, et al.
Publicado: (2015)

Development of Highly Organized Lymphoid Structures in Buruli Ulcer Lesions after Treatment with Rifampicin and Streptomycin
por: Schütte, Daniela, et al.
Publicado: (2007)

Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria
por: Ruf, Marie-Thérèse, et al.
Publicado: (2017)

Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model
por: Bolz, Miriam, et al.
Publicado: (2016)

Mycobacterium ulcerans Persistence at a Village Water Source of Buruli Ulcer Patients
por: Bratschi, Martin W., et al.
Publicado: (2014)

Experimental Infection of the Pig with Mycobacterium ulcerans: A Novel Model for Studying the Pathogenesis of Buruli Ulcer Disease
por: Bolz, Miriam, et al.
Publicado: (2014)

Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens
por: Bratschi, Martin W, et al.
Publicado: (2014)

Developing a Buruli ulcer community of practice in Bankim, Cameroon: A model for Buruli ulcer outreach in Africa
por: Awah, Paschal Kum, et al.
Publicado: (2018)

Immunohistochemical Monitoring of Wound Healing in Antibiotic Treated Buruli Ulcer Patients
por: Andreoli, Arianna, et al.
Publicado: (2014)

Identification of the Mycobacterium ulcerans Protein MUL_3720 as a Promising Target for the Development of a Diagnostic Test for Buruli Ulcer
por: Dreyer, Anita, et al.
Publicado: (2015)

Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions
por: Ogbechi, Joy, et al.
Publicado: (2015)

Late Onset of the Serological Response against the 18 kDa Small Heat Shock Protein of Mycobacterium ulcerans in Children
por: Röltgen, Katharina, et al.
Publicado: (2014)

Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms
por: Bibert, Stéphanie, et al.
Publicado: (2017)

Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana
por: Addison, Naa Okaikor, et al.
Publicado: (2017)

Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment
por: Scherr, Nicole, et al.
Publicado: (2015)

Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection?
por: Ruf, Marie-Thérèse, et al.
Publicado: (2011)

“It Is Me Who Endures but My Family That Suffers”: Social Isolation as a Consequence of the Household Cost Burden of Buruli Ulcer Free of Charge Hospital Treatment
por: Peeters Grietens, Koen, et al.
Publicado: (2008)

On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer
por: Doig, Kenneth D, et al.
Publicado: (2012)

Secondary Bacterial Infections of Buruli Ulcer Lesions Before and After Chemotherapy with Streptomycin and Rifampicin
por: Yeboah-Manu, Dorothy, et al.
Publicado: (2013)

Correction: “It Is Me Who Endures but My Family That Suffers”: Social Isolation as a Consequence of the Household Cost Burden of Buruli Ulcer Free of Charge Hospital Treatment
por: Peeters Grietens, Koen, et al.
Publicado: (2008)

Correction: “It Is Me Who Endures but My Family That Suffers”: Social Isolation as a Consequence of the Household Cost Burden of Buruli Ulcer Free of Charge Hospital Treatment
por: Peeters Grietens, Koen, et al.
Publicado: (2008)

Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue?
por: Ruf, Marie-Thérèse, et al.
Publicado: (2011)

Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer
por: Bolz, Miriam, et al.
Publicado: (2016)

Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection With Mycobacterium ulcerans
por: Röltgen, Katharina, et al.
Publicado: (2020)

Targeting the Mycobacterium ulcerans cytochrome bc(1):aa(3) for the treatment of Buruli ulcer
por: Scherr, Nicole, et al.
Publicado: (2018)

What Role Do Traditional Beliefs Play in Treatment Seeking and Delay for Buruli Ulcer Disease?–Insights from a Mixed Methods Study in Cameroon
por: Peeters Grietens, Koen, et al.
Publicado: (2012)

Single Nucleotide Polymorphism Typing of Mycobacterium ulcerans Reveals Focal Transmission of Buruli Ulcer in a Highly Endemic Region of Ghana
por: Röltgen, Katharina, et al.
Publicado: (2010)

Mycobacterium ulcerans DNA in Bandicoot Excreta in Buruli Ulcer–Endemic Area, Northern Queensland, Australia
por: Röltgen, Katharina, et al.
Publicado: (2017)

Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice
por: Bieri, Raphael, et al.
Publicado: (2016)

Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital
por: Please, Helen R., et al.
Publicado: (2021)

Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions
por: Hsieh, Louise Tzung-Harn, et al.
Publicado: (2022)

Socio-Environmental Factors Associated with the Risk of Contracting Buruli Ulcer in Tiassalé, South Côte d’Ivoire: A Case-Control Study
por: N’krumah, Raymond T. A. S., et al.
Publicado: (2016)

Geographic Expansion of Buruli Ulcer Disease, Cameroon
por: Marion, Estelle, et al.
Publicado: (2011)

Burden and Historical Trend of Buruli Ulcer Prevalence in Selected Communities along the Offin River of Ghana
por: Ampah, Kobina Assan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iv3ealkqvqq3kkvhnmvi42va4r